BAN2401 is an investigational medication being studied for the treatment of early Alzheimer’s disease. It is designed to target and remove harmful proteins in the brain that are believed to contribute to the progression of Alzheimer’s disease. The medication aims to slow down cognitive decline and improve daily functioning in people with early-stage Alzheimer’s disease.

Mild Cognitive Impairment due to Alzheimer’s Disease – A condition characterized by noticeable decline in memory and thinking skills that is greater than normal age-related changes but not severe enough to significantly impact daily activities. It represents an early stage of cognitive decline where a person experiences memory lapses, difficulty with complex tasks, and mild problems with judgment or reasoning. The condition primarily affects memory, particularly the ability to learn and recall new information. People with this condition maintain their independence in everyday activities but may take longer to complete tasks or make more mistakes than before.

Mild Alzheimer’s Disease Dementia – The early stage of Alzheimer’s disease where cognitive decline becomes more pronounced than in mild cognitive impairment. During this stage, individuals experience increasing difficulty with memory, particularly in remembering recent events and learning new information. People may have trouble with planning, organization, and handling complex tasks that they previously managed well. They might experience mild language difficulties, such as finding the right words, and may become confused about time or place occasionally. Despite these challenges, individuals in this stage can still function somewhat independently with some assistance.